Adami S, Frijlink W B, Bijvoet O L, O'Riordan J L, Clemens T L, Papapoulos S E
Calcif Tissue Int. 1982 Jul;34(4):317-20. doi: 10.1007/BF02411260.
In 10 patients with Paget's disease of bone and 2 patients with osteoporosis, we studied the effects of hypocalcemia and hypophosphatemia induced by disodium-(3-amino-1-hydroxypropylidene)-1,-bisphosphonate (APD) treatment on the serum concentration of PTH and 1,25-dihydroxy-vitamin D [1,25(OH)2D3] and on calcium absorption and balance. The fall in serum calcium and phosphate was associated with a rise in the serum concentration of PTH and 1,25(OH)2D3, coupled with increases in net calcium absorption and calcium balance. The concentration of 1,25(OH)2D3 was significantly related (P less than 0.001) to the serum calcium (r = 0.66), the serum phosphate (r = 0.78), and the serum PTH (r = 0.71), confirming the interrelated control of these parameters on 1,25(OH)2D3 production. Moreover the rise in 1,25(OH)2D3 caused an appropriate rise in calcium absorption (r = 0.74) and calcium balance (r = 0.86), showing that this vitamin D metabolite contributes as a hormone to calcium homeostasis.
在10例骨佩吉特病患者和2例骨质疏松症患者中,我们研究了(3-氨基-1-羟基亚丙基)-1,1-二膦酸二钠(APD)治疗诱导的低钙血症和低磷血症对血清甲状旁腺激素(PTH)浓度、1,25-二羟维生素D[1,25(OH)₂D₃]浓度以及钙吸收和平衡的影响。血清钙和磷的下降与血清PTH和1,25(OH)₂D₃浓度的升高相关,同时净钙吸收和钙平衡增加。1,25(OH)₂D₃的浓度与血清钙(r = 0.66)、血清磷(r = 0.78)和血清PTH(r = 0.71)显著相关(P < 0.001),证实了这些参数对1,25(OH)₂D₃产生的相互关联的调控。此外,1,25(OH)₂D₃的升高导致钙吸收(r = 0.74)和钙平衡(r = 0.86)相应升高,表明这种维生素D代谢产物作为一种激素对钙稳态有贡献。